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AbstrAct:
In the last 6 years, since the first reports of an association between somatic mutations 
in epidermal growth factor receptor (EGFR) exons 19 and 21 and response to EGFR 
tyrosine kinase inhibitors (TKIs), treatment of non-small cell lung cancer (NSCLC) has 
changed dramatically. Based on laboratory and clinical observations, investigators 
have anticipated that these mutations could be predictive of response to EGFR TKIs and 
numerous studies have confirmed that the presence of mutation was associated with 
longer survival in patients receiving targeted therapy. Prospective trials comparing 
standard platinum-based chemotherapy with EGFR TKIs in patients with and without 
activating EGFR mutations validated the predictive value of molecular selection of 
patients for first-line treatment of advanced NSCLC. Recently, preclinical and first-
in-human  studies  have  demonstrated  impressive  activity  of  ALK  TKI  in  tumors 
harboring ALK rearrangement. In this article, we review current data on molecular 
biology of lung cancer and evidence-based patient selection for targeted therapy.
IntroductIon
Lung cancer is the most frequent cause of cancer-
related death worldwide. Non-small cell lung cancer 
(NSCLC) accounts for 85% of all lung cancers [1]. Only 
a minority of NSCLC patients is suitable for radical 
treatment as curative care. Most patients have advanced 
disease at diagnosis and palliative therapy is the mainstay 
of management. Conventional chemotherapy of NSCLC 
has apparently reached a plateau of effectiveness in 
improving survival of lung cancer patients, and treatment 
outcomes must still be considered disappointing [2]. 
Based on a better understanding of the biology of lung 
cancer, targeted therapies are also available to treat 
patients with NSCLC. Predictive markers of response to 
these agents are undergoing prospective validation and 
promising results have been reported. 
The epidermal growth factor receptor (EGFR) 
signaling pathway is importantly implicated in tumor cell 
growth, local invasion, angiogenesis, metastasis, protein 
translation and cell metabolism. It activates two major 
pathways in solid tumors, RAS/RAF/MAPK/ERK and 
PI3K/AKT/mTOR, as seen in Figure 1 [3]. Molecular 
aberrations on the EGFR pathway are the most commonly 
studied predictive biomarkers of response/ resistance to 
targeted agents in lung cancer. This review delineates 
the current role of EGFR inhibitors in the treatment 
of advanced NSCLC according to EGFR and KRAS 
status of the tumor, strategies to overcome resistance to 
agents targeting EGFR and also discusses other recently 
discovered molecular aberration in lung cancer, ALK 
rearrangement, which is being efficiently targeted with 
ALK inhibitors.
EGFr pAthwAy: molEculAr 
AbErrAtIons, AntI-EGFr thErApy 
And prEdIctIvE mArkErs oF 
rEsponsE
NSCLC is associated with EGFR overexpression in 
up to 80% of the patients and a high EGFR gene copy 
number is found in nearly 60% of the cases [4-6]. Mutation 
of the EGFR proto-oncogene is found in 10% to 20% of Oncotarget 2011; 2:  165 - 177 166 www.impactjournals.com/oncotarget
lung carcinomas (mostly adenocarcinomas) and nearly 
90% of lung cancer-specific EGFR mutations comprise a 
leucine-to-arginine substitution at position 858 (L858R) 
and deletion mutations in exon 19 (delE746-A750) [7-
10]. These mutations cause constitutive activation of 
the tyrosine kinase of the EGFR [11]. DNA sequencing 
is the most accurate method for identification of EGFR 
mutations in tissue samples. Using polymerase-chain 
reaction (PCR) amplification, deletions in exon 19 and 
exon 21 point mutations in codon 858 can be detected 
by length analysis and specific probes for wild-type and 
mutant sequences [12]. In addition, the Scorpion Amplified 
Refractory Mutation System (SARMS) technology can be 
used to detect EGFR mutations in serum genomic DNA or 
circulating lung-cancer cells [13, 14]. 
The EGFR kinase domain can be targeted with 
tyrosine kinase inhibitors (TKIs), such as erlotinib 
and  gefitinib.  In  addition,  another  strategy  to  inhibit 
EGFR activity is with monoclonal antibodies such as 
cetuximab, a human-mouse chimeric IgG1 agent. It has 
been demonstrated that a subgroup of NSCLC patients 
achieves impressive response rates (RR), symptomatic 
improvement and long-term progression-free survival 
(PFS)  with  these  agents.  Since  the  first  reports  of  an 
association between somatic mutations in EGFR exons 19 
and 21 and response to gefitinib, treatment of NSCLC has 
changed dramatically [7, 8]. It has been shown that exon 
19 deletions are more sensitive to erlotinib inhibition than 
the L858R mutation, a finding demonstrated by kinetic 
analysis [15] and also confirmed in clinical studies [16-
18]. On the other hand, cetuximab is not as potent as 
EGFR TKIs in tumors with exon 19 deletion or L858R 
EGFR mutations [19]. 
Differences in the design of the clinical studies and 
technical approaches have led to some confusion about 
the role of molecular diagnostics in guiding the use of 
EGFR-targeted therapy in NSCLC. Most information 
regarding clinical benefit with these agents comes from 
retrospective analysis of large studies. At the present time, 
prospective clinical data confirming the predictive value of 
receptor mutations for response to EGFR TKIs is available 
[20, 21]. Apart from mutation analysis, EGFR protein 
expression determined by immunohistochemistry (IHC) 
and EGFR gene copy number determined by fluorescent 
in situ hybridization (FISH) have been evaluated as 
markers for clinical decision making regarding EGFR 
TKI therapy. Technical considerations are important in 
assessing IHC, which suffers from the lack of a standard 
methodology and inconsistencies among testing centers 
[6]. In addition, gene copy number evaluation by FISH 
Figure 1: Epidermal Growth Factor receptor (EGFr) pathway and anti-EGFr therapy in clinical use.Oncotarget 2011; 2:  165 - 177 167 www.impactjournals.com/oncotarget
may be affected by tumor heterogeneity within analyzed 
specimens. Therefore, a detailed review of the clinical 
trials evaluating molecular markers of response to anti-
EGFR agents is warranted. 
rEvIEw oF clInIcAl trIAls wIth 
AntI-EGFr AGEnts In nsclc
Gefitinib and Erlotinib
Phase  I  studies  of  gefitinib  defined  dose-limiting 
toxicities at 700 to 1000 mg/day [22, 23]. However, 
pharmacodynamic data showed that a dose of 150 mg/
day was sufficient to suppress EGFR signaling in skin 
biopsy specimens [24]. As chronic daily doses higher than 
500 mg/day were relatively not well tolerated, further 
studies evaluated 250 and 500 mg/day doses. Gefitinib 
was examined as monotherapy in two phase II studies 
called IDEAL trials [25, 26]. Response rates with doses 
of 250 and 500 mg/day were similar, ranging from 10% to 
18%. Notably, responses were more likely in patients with 
specific  characteristics:  Asians,  females,  non-smoking 
and those with adenocarcinoma tumors. Posterior analysis 
demonstrated that patients with and EGFR mutation 
had an improved RR to gefitinib compared to wild-type 
patients (46% versus 10%), as shown in Table 1 [27]. 
The early trials that evaluated EGFR TKIs for the 
second- and third-line settings of advanced NSCLC did 
not select patients on the basis of any EGFR marker [28, 
29]. The ISEL trial evaluated the role of second-line 
gefitinib  250  mg/day  in  1,692  patients  with  advanced 
NSCLC [29]. Median overall survival (OS) was 5.6 
months, compared to 5.1 months in the placebo group, 
difference not statistically significant. High EGFR gene 
copy number (30.8% of patients) was associated with a 
nonsignificant trend toward improved OS with gefitinib 
treatment and patients with EGFR mutations had higher 
RR than patients without (37.5% versus 2.6%) [30]. In the 
INTEREST trial, 1,466 pretreated patients with advanced 
NSCLC were randomly assigned to receive gefitinib or 
docetaxel in the second-line setting [31]. Non-inferiority 
of gefitinib compared to docetaxel was confirmed for OS 
(7.6 versus 8.0 months). EGFR mutation-positive patients 
had significantly longer PFS (HR – Hazard Ratio = 0.16) 
and higher objective RR (42.1% versus 21.1%) with 
gefitinib compared to docetaxel. Patients with high EGFR 
copy  number  also  had  higher  RR  with  gefitinib (13% 
versus 7.4%) [32]. 
Table 1: Response rate to EGFR tyrosine kinase inhibitors according to EGFR mutation status
EGFR mutation (+) EGFR mutation (-)
Reference
% (patients) % (patients)
Gefitinib
Retrospective evaluation
IDEAL trial  46% (13) 10% (56) 27
ISEL trial  37% (16) 2% (116) 30
INTEREST trial 42% (19) NR 32
Prospective evaluation
Inoue et al. 75% (16) - 43
Sequist et al. 55% (31) - 45
Kim et al. 53% (45) - 18
Erlotinib
Retrospective evaluation
BR.21  27% (15) 7% (101) 36
Janne et al. 66% (32) 8% (48) 47
Prospective evaluation
Spanish Lung Cancer trial 70% (217) - 16
NR: not reportedOncotarget 2011; 2:  165 - 177 168 www.impactjournals.com/oncotarget
In  contrast  to  gefitinib,  dose  of  erlotinib  studied 
in phase II and III trials is the maximum-tolerated dose 
defined in phase I trials (150 mg/ day) [33]. A phase II 
trial  in  patients  with  refractory  NSCLC  confirmed  RR 
of approximately 12% and survival outcomes similar 
to gefitinib [34]. The BR.21 study (erlotinib in second- 
and third-line settings of advanced NSCLC) found 
superiority in survival with erlotinib group as compared 
to placebo (median OS of 6.7 versus 4.7 months) [28]. 
Molecular analysis of BR.21 trial showed that FISH 
positivity (45% of tumors) was predictive of improved 
survival with erlotinib (HR = 0.44) [35]. EGFR mutations 
were  confirmed  in  17%  of  tumors  (34  patients  had 
classical EGFR activating mutations). Response rate was 
significantly higher in patients with these mutations (27% 
versus 7%) compared to patients with wild-type or other 
indeterminate mutations [36]. This trial also confirmed 
symptomatic and survival benefit of erlotinib in patients 
without initial clinical predictors of response to EGFR 
TKIs  [37].  One  possible  explanation  to  this  finding  is 
that erlotinib was administered at its maximum-tolerated 
dose, which could have different effects in the population 
of patients with wild-type EGFR, not hypersensitive to 
EGFR TKIs. This correlates with the higher prevalence of 
rash, a known marker of efficacy with these agents, in the 
erlotinib trial (76%, as compared to 37% in the gefitinib 
trial) [38]. 
Another study with relevant molecular data is the 
SATURN trial, which randomly assigned 889 patients with 
advanced NSCLC who had response or stable disease after 
four cycles of platinum-based chemotherapy to erlotinib 
or placebo as maintenance treatment [39]. Progression-
free survival was significantly improved in the erlotinib 
maintenance arm (HR = 0.71). Tumor biomarker analysis 
of EGFR mutation status was available for 437 patients: 
those with EGFR mutation had median PFS of 44.6 weeks 
on erlotinib compared to 13 weeks with placebo (HR = 
0.1), a remarkable benefit for this subgroup of patients. 
EGFR  mutation  was  the  only  marker  significantly 
predictive of differential erlotinib effect [39]. 
Cetuximab
In the FLEX trial, 1,125 patients with advanced 
NSCLC and EGFR-positive tumors by IHC were 
randomly assigned to chemotherapy plus cetuximab or 
chemotherapy alone [40]. Patients given chemotherapy 
plus cetuximab survived longer than those in the 
chemotherapy-alone group (median OS of 11.3 versus 
10.1 months; HR for death 0.87, p = 0.044). Molecular 
biomarker study showed that no significant differences 
in survival were detected between patients with FISH 
positive or negative tumors in either treatment arm [41]. 
As anticipated by preclinical data, EGFR mutation status 
(positive in 17% of cases) was not predictive of benefit 
with cetuximab. However, the prognostic value of 
mutation was confirmed, with longer overall survival in 
patients with EGFR mutation tumors compared to wild-
type tumors in both treatment arms [41]. 
A similar trial was carried out in the USA in 676 
nonselected patients with advanced NSCLC (BMS099) 
[42].  There  was  no  survival  benefit  with  the  addition 
of cetuximab to paclitaxel-carboplatin combination 
chemotherapy. Tissue samples for biomarker subanalysis 
were available for one-third of the patients. EGFR 
expression,  EGFR copy number and EGFR mutations 
were not associated with treatment outcomes [42].
prospEctIvE studIEs wIth 
EGFr-tkIs In sElEctEd pAtIEnt 
populAtIons
Studies with first-line EGFR TKIs in advanced lung 
cancer have been recently reported. The first study was 
conducted in Asian patients and examined EGFR status in 
75 patients [43]. Sixteen patients with EGFR mutation were 
enrolled onto the study and received gefitinib 250 mg/day. 
Overall RR was 75% and median PFS was 9.7 months. 
As seen in Table 1, a confirmatory trial with gefitinib as 
first-line  treatment  of  advanced  EGFR  mutant  NSCLC 
reported RR of 53% in 45 patients [18]. Interesting data 
came from another prospective trial in Japan that enrolled 
30 patients with EGFR mutations and poor Performance 
Status (PS) without indication for palliative chemotherapy 
[44]. The overall RR was 66% and the disease control rate 
was 90%. Of note, 15 of 22 patients with baseline PS 3 
improved to PS 1. Median PFS and OS were 6.5 months 
and 17.8 months, respectively [44].
Prospective screening studies in non-Asian 
populations  have  also  been  reported.  The  first  study 
screened chemotherapy-naïve patients with advanced 
NSCLC and clinical characteristic associated with EGFR 
mutations [45]. Response rate was 55% in 31 patients who 
received gefitinib and the median PFS was 9.2 months. 
The authors also evaluated EGFR gene copy number by 
FISH and concluded that it did not provide additional 
predictive information. This was because most patients 
who harbor EGFR mutations also had high gene copy 
numbers [46]. The Spanish Lung Cancer Group trial 
observed a prevalence of EGFR mutations in patients 
with lung cancer in Spain around 16% (350 of 2,105 
cases) [16]. In 60% of the patients, EGFR mutations were 
also detected in the serum. Median PFS and OS for 217 
patients who received erlotinib were 14 months and 27 
months, respectively, and radiologic RR was around 70%. 
Duration of response was similar for patients receiving 
first-line therapy (14 months) or second-line therapy (13 
months) [16].
Recently, results of the phase II randomized trial 
of erlotinib compared to erlotinib in combination with 
paclitaxel-carboplatin chemotherapy in treatment-
naïve, never or light former smokers with advanced lung Oncotarget 2011; 2:  165 - 177 169 www.impactjournals.com/oncotarget
adenocarcinoma [47]. Of the 182 patients randomized, 67 
(39%) had mutant and 105 (61%) wild-type EGFR. In 
the overall patient population, addition of chemotherapy 
did not significantly increase response rate or PFS. EGFR 
mutant patients had median PFS of 15.7 months with 
single-agent erlotinib as compared to 17.2 months with 
combination therapy. On the other hand, PFS in patients 
with tumors harboring wild-type EGFR was only 2.4 
months with single-agent erlotinib and 4.8 months with 
the addition of chemotherapy [47]. 
Based on these findings, several phase III trials are 
comparing first-line treatment of advanced NSCLC with 
chemotherapy or EGFR TKI in specific populations of 
patients: (a) in a clinically-enriched subgroup; or (b) in 
a biomarker-selected subgroup - those with documented 
EGFR  exon  19  or  21  mutations.  The  first  published 
trial, named IPASS, selected more than 1,200 patients 
to receive gefitinib 250 mg/day or standard paclitaxel-
carboplatin chemotherapy [17]. Only patients with clinical 
characteristics predictive of response to EGFR TKIs 
were enrolled (adenocarcinoma histology; nonsmokers, 
defined as patients who had smoked <100 cigarettes in 
their lifetime; or former light smokers, defined as those 
who had stopped smoking at least 15 years previously 
and had a total of ≤10 pack-years of smoking). The study 
met its primary objective of showing the noninferiority of 
gefitinib and also showed its superiority, as compared to 
chemotherapy, with regards to PFS (HR for progression 
or death = 0.74). The 12-months rates of PFS were 24.9% 
with  gefitinib  and  6.7%  with  paclitaxel-carboplatin. 
However, the overall population result is clearly of less 
relevance than the outcome in subgroups of patients. As 
shown in Table 2, in the 261 patients who were positive 
for  the  EGFR  mutation,  PFS  was  significantly longer 
among  those  who  received  gefitinib  than  among  those 
who received paclitaxel-carboplatin (HR = 0.48), whereas 
in the subgroup of 176 patients who were negative for the 
mutation, PFS was significantly longer among those who 
received chemotherapy (HR for progression or death with 
gefitinib  =  2.85).  In  the  mutation-negative  population, 
objective RR was only 1.1% with gefitinib versus 23.5% 
with chemotherapy. High EGFR copy number by FISH 
was predictive for efficacy only when accompanied by the 
presence of concomitant EGFR mutation. Patients with 
a high EGFR copy number and wild-type EGFR did not 
benefit from gefitinib, but did benefit from chemotherapy 
[17]. No difference in OS was seen in patients with EGFR 
mutation regardless of the treatment assigned [48]. The 
major reason for the lack of survival benefit is the cross-
over effect, as half of the patients in the chemotherapy 
arm received EGFR TKIs at disease progression [48]. The 
second trial assigned 309 chemotherapy-naïve patients 
with adenocarcinomas who had never smoked to receive 
250 mg gefitinib daily or gemcitabine plus cisplatin at 
standard doses [49]. Progression-free survival was similar 
in both arms (6.1 months for gefitinib, 6.6 months for 
Table 2: Prospective randomized studies of first-line EGFR TKIs versus standard chemotherapy in clinically-enriched 
and biomarker-selected patient populations
Study  Population Treatment Arms Response Rate Progression-free survival 
(favoring EGFR TKI)
Overall survival Reference
IPASS
Asians, never/ former 
light smokers, 
adenocarcinoma          
(216 patients with 
EGFR mutation)
Gefitinibx          
Paclitaxel/ Carboplatin
71% x 47%           HR 0.48 (0.36 -0.64)           HR 1.0               
(0.76-1.33)        17
First-SIGNAL
Asians, never smokers, 
adenocarcinoma                   
(26 patients with EGFR 
mutation received 
gefitinib)
Gefitinib x    
Gemcitabine/ Cisplatin
85% x 37%           8.4 x 6.7 months (NS)  Not available  49
North-East Japan EGFRmutation,             
200 patients
Gefitinib x         
Paclitaxel/ Carboplatin
74% x 31% 10.8 x 5.4 months            
HR 0.31 (0.22 -0.41)
30.5 x 23.6 
months (NS)
20
WJTOG3405 EGFRmutation,             
177 patients
Gefitinibx           
Docetaxel/ Cisplatin
62% x 32% 9.2 x 6.3 months 
HR 0.49 (0.34-0.71)
Not available 21
OPTIMAL EGFRmutation,          
165 patients
Erlotinib x     
Gemcitabine/ 
Carboplatin
83% x 36% 13.1 x 4.6 months 
HR 0.16 (0.10-0.26)
Not available 50
EURTAC
EGFRmutation, 
approximately 170 
patients
Erlotinib x             
Platinum doublet
Pending Pending Pending
LUX-Lung 3/       
LUX-Lung 6
EGFRmutation, 
approximately 330 
patients each study
BIBW2992 x 
Pemetrexed/ Cisplatin 
or Gemcitabine/ 
Cisplatin
Pending Pending Pending
HR: HazardRatio, NS: non significantOncotarget 2011; 2:  165 - 177 170 www.impactjournals.com/oncotarget
chemotherapy) and in the subgroup of patients with known 
EGFR mutations (44%), gefitinib produced a higher RR, 
as shown in Table 2 [49]. Both studies emphasize the 
importance of molecular selection of patients for first-line 
treatment with an EGFR TKI. 
Preliminary results of other phase III trials that 
randomized patients with metastatic NSCLC and EGFR 
mutations at baseline to receive EGFR TKIs or standard 
first-line platinum-based regimens are presented in Table 
2. The North-East Japan trial (prematurely interrupted after 
interim analysis) and the WJTOG3405 trial demonstrated 
that  treatment  with  gefitinib  doubles  the  RR  and 
significantly improves PFS as compared to chemotherapy 
[20, 21]. The first study with erlotinib as comparator was 
recently presented. In the OPTIMAL trial, Asian patients 
with chemonaïve NSCLC with EGFR mutations were 
randomized to erlotinib 150 mg/day or gemcitabine plus 
carboplatin [50]. Both RR and PFS were higher in the 
EGFR TKI subgroup [50]. Additional prospective studies 
are underway, as seen in Table 2. 
ovErcomInG rEsIstAncE to EGFr 
tkIs
Tumors become resistant when they reactivate 
downstream signaling despite the presence of the EGFR 
inhibitor. Zhang et al. summarize the current understanding 
of the functional role of activating EGFR mutations in 
addition to the pivotal primary and acquired resistance 
mechanisms to EGFR inhibitors [51]. Resistance is 
typically caused by mutations in the EGFR gene that 
are not associated with sensitivity to EGFR TKIs, such 
as insertion mutations in exon 20 [52], or by other 
somatic mutations in genes that have an impact on the 
EGFR signaling pathway, such as KRAS [53]. Acquired 
resistance may be caused by additional mutations in the 
EGFR gene obtained during the course of treatment that 
change the protein-coding sequence or by amplification of 
another oncogene signaling pathway [54]. 
The  most  commonly  identified  mechanism  of 
resistance is an EGFR mutation at position 790 (T790M), 
resulting in substitution of a threonine residue with 
methionine,  which  abrogates  the  ability  of  gefitinib  or 
erlotinib to inhibit EGFR [55, 56]. This mutation can 
be found in 50% of the tissue samples from patients 
with acquired gefitinib resistance [57]. Another acquired 
mutation in EGFR, which leads to substitution of alanine 
for threonine at position 854 (T854A) and hinders the 
inhibition of tyrosine phosphorylation by erlotinib, has also 
been reported [58]. Various irreversible EGFR inhibitors, 
such as BIBW2992/ afatinib (targeting EGFR and HER2) 
and PF00299804 (targeting EGFR, HER2 and HER4) 
are undergoing clinical development. These agents may 
prevent and overcome primary and acquired resistance to 
first-generation reversible EGFR TKIs. In the LUX-Lung 
2 study, 129 patients with activating EGFR mutations and 
no previous EGFR TKI therapy received BIBW2992 as 
single agent [59]. Overall RR was 60%, with a promising 
PFS of 14 months. This drug has also shown activity in 
patients whose tumors harbored less common EGFR 
mutations  [60].  Its  efficacy  was  also  evaluated  as  a 
rescue treatment after failure to erlotinib or gefitinib in a 
randomized phase III trial [61]. At primary analysis (358 
events in 585 patients), median OS was 10.8 months in the 
BIBW2992 group and 11.9 months in the placebo group. A 
significant PFS increase was seen in patients that received 
the study drug (3.3 versus 1.1 months) [61]. Regarding 
the PF00029804 compound, preliminary data from a 
phase II randomized trial showed that PFS was superior 
when compared to erlotinib in the general population 
of patients with chemotherapy-refractory NSCLC, not 
selected according to EGFR mutation status (12.4 weeks 
versus 8.3 weeks) [62]. As first-line treatment of patients 
with known EGFR mutation or clinically selected (Asians 
with adenocarcinoma and non-or light smoking history), 
PF00029804 showed encouraging efficacy, with 6 month-
PFS rate of 67% (85% in those with EGFR mutation) [63]. 
Activation of downstream signaling via alternative 
mechanisms that stimulate the RAS/RAF/MAPK/ERK 
and PI3K/AKT/mTOR pathways is another mechanism of 
resistance to EGFR TKIs. This occurs with activation of the 
IGF-1R pathway (Insulin-like Growth Factor 1 Receptor) 
[64], amplification/ mutations of MET (the receptor for 
hepatocyte growth factor receptor, identified in 10-20% of 
NSCLC) [65-67], and PIK3CA amplification/ mutations 
(identified in up to 17% of NSCLC) [68]. In this situation, 
there appears to be dual input to signaling and combined 
inhibition of EGFR and the alternative pathway may be 
necessary to kill tumor cells. A combination approach 
may prevent the emergence of resistance that eventually 
occurs following initial response to EGFR TKIs and may 
increase the proportion of EGFR wild-type patients that 
respond. Preliminary data of a phase II randomized trial 
of erlotinib and placebo or in combination with a non-
ATP competitive receptor TKI of c-MET (ARQ 197) were 
recently presented [69]. Progression-free survival was 
significantly higher for the dual inhibition approach (HR 
= 0.68, p < 0.05) [69]. A monoclonal antibody targeting 
MET (MetMab) is also under clinical development. In 
patients with advanced NSCLC and MET expression by 
IHC analysis, the combination of erlotinib and MetMab 
significantly  increased  PFS  (HR  =  0.56,  p  =  0.05)  as 
compared to erlotinib and placebo in a phase II randomized 
trial [70]. Multiple phase I and II trials are underway to 
evaluate the additive benefit of other targeted agents, such 
as anti-IGF1R monoclonal antibodies, PI3K/mTOR and 
MEK inhibitiors.
KRAS stAtus And rEsponsE to AntI-
EGFr AGEnts
KRAS mutations were identified in NSCLC tumors Oncotarget 2011; 2:  165 - 177 171 www.impactjournals.com/oncotarget
more than 20 years ago [71]. KRAS encodes a GTPase 
downstream of EGFR and mutations (most frequent 
in exons 12, 13 and 61) lead to stimulus-independent, 
persistent activation of downstream effectors of the RAF/
MAPK/MEK/ERK cascade [72]. They are associated 
with significant tobacco exposure and worse prognosis, 
although contradictory data have been reported [73, 74]. 
Prevalence of mutation is about 20% in the overall lung 
cancer patient population, 5% to 15% in never-smokers 
patients with adenocarcinoma and approximately 5% in 
the squamous cell carcinoma subtype [75-77]. 
KRAS mutations are associated with primary 
resistance to EGFR TKIs [78]. Phase II trials have shown 
very small or absent response rates to erlotinib in patients 
with KRAS mutations [79]. A recent meta-analysis 
demonstrated 3% rate of objective tumor response 
to EGFR TKIs in patients with KRAS mutations, as 
compared to 26% in those with wild-type KRAS [80]. 
Data from the TRIBUTE trial (chemotherapy with or 
without erlotinib for previously untreated patients with 
NSCLC) suggest that, in KRAS mutated patients, OS and 
RR may be worse with the addition of EGFR TKI [81]. 
KRAS mutant patients (20% of available tumor samples) 
showed a RR of 8% with paclitaxel-carboplatin plus 
erlotinib, compared with 23% for patients that received 
the chemotherapy doublet alone. Of note, the RR for 
patients treated with chemotherapy alone did not differ 
significantly  by  KRAS  mutation  status  (26%  in  those 
without mutation versus 23%) [81]. In the INTEREST 
trial, KRAS mutation was not a predictive factor for a 
differential survival effect between gefitinib and docetaxel 
[32]. In the BR.21 trial, significant survival benefit from 
second- or third-line erlotinib therapy was observed for 
patients with wild-type KRAS (HR = 0.69, p=0.03) but 
not for patients with mutant KRAS (HR = 1.67, p = 0.31) 
[36]. Molecular data from the maintenance SATURN trial 
suggested that KRAS mutation was a negative prognostic 
factor for patients receiving placebo, with significantly 
shorter PFS (HR = 1.5, p = 0.017) [39]. Patients with 
wild-type KRAS had statistically significant benefit with 
erlotinib in terms of PFS (HR = 0.7, p = 0.0009). The 
hazard ratio for PFS was similar in the KRAS mutant 
population, but the benefit was not statistically significant 
(HR = 0.77, p = 0.22) [39]. 
Based on data from KRAS mutation status and 
benefit of cetuximab in advanced colon cancer, molecular 
analysis of FLEX trial was conducted. Of the 1,125 
patients enrolled, 395 had tumor samples available and 
KRAS mutation was detected in 19%. The comparison 
of the cetuximab treatment effects in patients with KRAS 
wild-type tumors and those with KRAS mutant tumors 
showed no marked differences with regard to PFS or OS 
[41]. In this trial, the benefit of cetuximab was observed 
regardless of KRAS mutational status. The same results 
were obtained with retrospective analysis of the BMS099 
trial [42]. Therefore, KRAS status does not predict 
sensitivity to cetuximab in NSCLC.
Alk rEArrAnGEmEnt And 
tArGEtEd thErApy 
A fusion gene between echinoderm microtubule-
associated protein like 4 (EML4) and the anaplastic 
lymphoma kinase (ALK) has recently been identified in 
NSCLC [82]. Although more frequent in hematological 
malignancies, recurrent chromosome translocations may 
play a role in the molecular pathogenesis of solid tumors. 
The fusion gene EML4-ALK, inv(2)(p21p23), becomes 
activated to exert a marked oncogenicity both in vitro and 
in vivo, possibly by switching on the RAS/RAF signaling 
pathway [83]. ALK rearrangement can be identified by 
FISH analysis using break-apart probes to ALK, which 
detects disruption of the ALK locus but does not confirm 
EML4 as the partner fusion gene. Recently, a novel highly 
sensitive antibody allowed for the routine detection of 
ALK-rearranged lung carcinomas by standard IHC [84].
Among 266 resected NSCLCs in an East Asian 
population, the EML4-ALK fusion gene was found in 
about 5% of cases, as assessed by reverse transcriptase-
PCR and posterior sequencing [85]. EML4-ALK was 
associated with younger age of cancer onset and with 
never-smoking status. EML4-ALK, EGFR, and KRAS 
mutations were all mutually exclusive, suggesting that 
ALK mutation may be an important oncogenic factor, 
and a potential therapeutic target in EGFR wild-type and 
KRAS wild-type lung cancer. When patients are selected 
for genetic screening on the basis of two or more of 
clinical characteristics (female sex, Asian ethnicity, never/
light smoking history, and adenocarcinoma histology), 
a recent study demonstrated that among 141 tumors 
evaluated, 19 (13%) were EML4-ALK mutant and 31 
(22%) were EGFR mutant [86]. Considering only never/ 
light smokers without EGFR mutation, the frequency of 
EML4-ALK was 33%. EML4-ALK positivity was related 
with resistance to EGFR TKIs but similar RR to platinum-
based combination chemotherapy. In addition, presence of 
EML4-ALK mutation was not associated differences in 
OS, as compared to those patients with wild type EML4-
ALK and EGFR [86]. 
Impressive clinical activity was demonstrated in 
a phase I trial of an oral ATP- competitive TKI of ALK 
and c-MET, crizotinib (PF-02341066), in patients with 
advanced NSCLC and whose tumors harbored ALK 
rearrangement by FISH analysis [87]. Patients enrolled 
shared several key clinical features with EGFR-mutated 
patients (adenocarcinoma histology and nonsmoking 
history). Among 82 patients treated in an expanded cohort 
of the dose-escalation study (250 mg twice daily), 57% 
had an objective RR and 72% were progression-free at 
6 months [87]. All patients tested negative for EGFR 
mutation  and  amplification  of  MET,  another  target  for 
crizotinib, which suggested that the therapeutic effect is Oncotarget 2011; 2:  165 - 177 172 www.impactjournals.com/oncotarget
through inhibition of ALK. Further confirmatory studies 
are underway, along with a phase III trial comparing 
treatment of ALK rearrangement positive patients with 
crizotinib or standard chemotherapy in the second-line 
setting. 
conclusIons
Identifying the patients who are most likely to obtain 
clinical benefit from targeted therapies in NSCLC is of 
paramount importance. To make rational clinical decisions, 
in addition to understanding the biology of the disease, 
oncologists need to rely on standardized and validated 
methods of molecular assessment. EGFR  amplification 
by FISH and protein expression measured by IHC are not 
informative for personalized therapy in advanced NSCLC 
but further analysis of studies that combine chemotherapy 
with monoclonal antibodies targeting EGFR is indicated. 
In addition, the value of determining KRAS mutation 
status to select EGFR TKI therapy is not clear. On 
the other hand, it is now well established that specific 
genetic lesions that drive the proliferation of cancer 
cells render some tumors very sensitive to therapeutic 
inhibitors targeting the mutated pathway. The most useful 
biomarker is EGFR mutation status and its determination 
is mandatory for proper therapeutic decisions. It is a 
good prognostic factor and has also predictive value for 
selecting treatment with EGFR TKIs. Different from 
the initially unsuccessful trials of EGFR inhibitors in 
nongenotyped patients, data from multiple phase III trials 
show  superiority  of  gefitinib/  erlotinib  over  standard 
chemotherapy for advanced NSCLC in terms of RR and 
PFS in the biomarker-selected EGFR mutation positive 
subgroup of patients. Additionally, ALK rearrangement is 
a promising biomarker of benefit with ALK inhibitors and 
its detection resulted in prompt translation of preclinical 
data to patient care. Only 3 years after the initiation of the 
phase I trial, a phase III registration study of crizotinib in 
ALK-positive patients started enrollment. Participation in 
a clinical trial is the best alternative for this subgroup of 
patients. Importantly, although EGFR and ALK mutations 
are found mostly in patients with history of no smoking 
or light smoking who have adenocarcinoma, genotyping 
should be offered to all patients with advanced NSCLC if 
treatment with specific TKIs is available. 
In conclusion, EGFR TKI therapy should be 
recommended to patients with activating EGFR mutations 
in the course of the disease. However, the lack of OS 
advantage with early treatment raises the question of 
whether we should give these drugs up-front, as maintenance 
therapy or as second-/ third-line options. Clinical practice 
in the treatment of advanced NSCLC patients has shown 
that progression and symptomatic deterioration can occur 
very short after treatment discontinuation. EGFR TKI 
therapy may be started once the mutation status is known: 
(a) as first-line therapy in all patients, especially those 
unfit or who do not agree with chemotherapy; and (b) 
as maintenance/ “early second-line” therapy for patients 
that received previous chemotherapy. Erlotinib may be 
considered a salvage treatment in unselected patient 
populations of chemotherapy-refractory NSCLC, as 
disease stabilization and symptomatic improvement was 
observed independent of molecular or clinical predictors 
of benefit. In addition, more clinical and translational data 
on irreversible EGFR inhibitors and dual targeted therapy 
in molecularly-selected subgroups of patients will help 
oncologists to personalize therapy of advanced NSCLC 
even further. 
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